Abstract
Phosphodiesterases (PDEs), as key regulators of cyclic nucleotides, and their inhibitors have been emerged as new pharmacological targets and promising drug candidates for many diseases, including central nervous system pathologies. The high level of PDE10A expression in the striatal medium spiny neurons suggests a prominent function role for the isoenzyme. Basal ganglia dysfunction is associated with neuropsychiatric disorders and until recently the development of PDE10A inhibitors has been focused on schizophrenia. Currently, the pharmaceutical research on PDE10A inhibitors is moving to show the modulation of other functions associated with the basal ganglia such the motor control. Thus, PDE10A inhibitors may be important pharmacological agents for neurodegenerative disorders such as Parkinson’s and Huntington’s diseases. Recent data supporting new clues for PDE10A as therapeutic target together with a concise review of the chemical structures of its inhibitors are provided here. The goal of this manuscript is to provide new ideas for assistant pharmacologist and medicinal chemists in the search for PDE10A inhibitors as new disease modifying drugs for Parkinson’s disease.
Keywords: cAMP, drug design, neurodegenerative diseases, Parkinson’s disease, PDE10A inhibitors.
Current Medicinal Chemistry
Title:Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Volume: 21 Issue: 10
Author(s): A.M. Garcia, M. Redondo, A. Martinez and C. Gil
Affiliation:
Keywords: cAMP, drug design, neurodegenerative diseases, Parkinson’s disease, PDE10A inhibitors.
Abstract: Phosphodiesterases (PDEs), as key regulators of cyclic nucleotides, and their inhibitors have been emerged as new pharmacological targets and promising drug candidates for many diseases, including central nervous system pathologies. The high level of PDE10A expression in the striatal medium spiny neurons suggests a prominent function role for the isoenzyme. Basal ganglia dysfunction is associated with neuropsychiatric disorders and until recently the development of PDE10A inhibitors has been focused on schizophrenia. Currently, the pharmaceutical research on PDE10A inhibitors is moving to show the modulation of other functions associated with the basal ganglia such the motor control. Thus, PDE10A inhibitors may be important pharmacological agents for neurodegenerative disorders such as Parkinson’s and Huntington’s diseases. Recent data supporting new clues for PDE10A as therapeutic target together with a concise review of the chemical structures of its inhibitors are provided here. The goal of this manuscript is to provide new ideas for assistant pharmacologist and medicinal chemists in the search for PDE10A inhibitors as new disease modifying drugs for Parkinson’s disease.
Export Options
About this article
Cite this article as:
Garcia A.M., Redondo M., Martinez A. and Gil C., Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?, Current Medicinal Chemistry 2014; 21 (10) . https://dx.doi.org/10.2174/0929867321666131228221749
DOI https://dx.doi.org/10.2174/0929867321666131228221749 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Co-Drug Strategy for Promoting Skin Targeting and Minimizing the Transdermal Diffusion of Hydroquinone and Tranexamic Acid
Current Medicinal Chemistry Genetic Modifications of Icosahedral Plant Virus-based Nanoparticles for Vaccine and Immunotherapy Applications
Current Protein & Peptide Science Feature Extraction and Classification of Epilepsy in Different Seizure Types: A Survey
Current Medical Imaging From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Melatonin Metabolism in the Central Nervous System
Current Neuropharmacology Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Current Neuropharmacology Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Cannabinoids and Neuroprotection in Motor-Related Disorders
CNS & Neurological Disorders - Drug Targets Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Role of Neurotrophic Factors in Parkinson's Disease
Current Pharmaceutical Design Integration of Internet of Things with Quantum Dots: A State-of-the-art of Medicine
Current Pharmaceutical Design Crofelemer: In HIV Associated Diarrhea and Secretory Diarrhea - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery The Role of Neurophysiological Biomarkers in Obsessive-Compulsive Disorder
Current Medicinal Chemistry Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews The Challenge of microRNA as a Biomarker of Epilepsy
Current Neuropharmacology Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?
Current Cancer Drug Targets Shear-Wave and Strain Elastography: A Comparative Review on Principles, Basic Techniques and Applications.
Current Medical Imaging